SPY400.09-1.63 -0.41%
DIA322.78+0.55 0.17%
IXIC11,662.79-142.21 -1.20%

BRIEF-Myovant Sciences Announces European Commission Approval For Orgovyx For The Treatment Of Advanced Hormone-Sensitive Prostate Cancer

reuters.com · 04/29/2022 19:15
BRIEF-Myovant Sciences Announces European Commission Approval For Orgovyx For The Treatment Of Advanced Hormone-Sensitive Prostate Cancer

- Myovant Sciences Ltd MYOV:

  • MYOVANT SCIENCES ANNOUNCES EUROPEAN COMMISSION APPROVAL FOR ORGOVYX® (RELUGOLIX) FOR THE TREATMENT OF ADVANCED HORMONE-SENSITIVE PROSTATE CANCER

  • APPROVAL IS APPLICABLE TO ALL 27 EUROPEAN UNION MEMBER STATES PLUS ICELAND, NORWAY, AND LIECHTENSTEIN

  • THIS APPROVAL WAS SUPPORTED BY DATA FROM PHASE 3 HERO STUDY

  • EXPECTS TO SECURE EUROPEAN COMMERCIALIZATION PARTNER AHEAD OF ANTICIPATED LAUNCHES

Source text for Eikon: ID:nGNX8cq9vB

Further company coverage: MYOV


((Reuters.Briefs@thomsonreuters.com;))